OTCMKTS:OREXQ Orexigen Therapeutics (OREXQ) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free OREXQ Stock Alerts $0.0053 +0.00 (+35.90%) (As of 05/31/2019) Add Compare Share Share Today's Range$0.0027▼$0.005350-Day Range$0.0053▼$0.005352-Week Range$0.00▼$0.16Volume60,300 shsAverage Volume80,439 shsMarket Capitalization$100,101.10P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Orexigen Therapeutics alerts: Email Address Ad StockEarningsThe AI Stock that’s Disrupting Every IndustryMove over Nvidia. There’s a new hot AI play that has soared 960% in the past year. One high-flying artificial intelligence stock has soared 960% over the past year and may soon become as familiar as Nvidia…Here's the Ticker >>> About Orexigen TherapeuticsOrexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Read More OREXQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OREXQ Stock News HeadlinesFebruary 2, 2024 | investing.comAxsome Therapeutics Inc (AXSM)November 4, 2023 | morningstar.comHeron Therapeutics Inc HRTXMay 3, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.February 19, 2023 | thestreet.comOrexigen Therapeutics (OREX) Stock Climbs on $60 Million InvestmentJanuary 18, 2022 | thestreet.comOrexigen Therapeutics (OREX) Stock Declines After Halting Heart Benefit TestsNovember 5, 2021 | markets.businessinsider.comWall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma BroSee More Headlines Receive OREXQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orexigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:OREXQ CUSIPN/A CIK1382911 Webwww.orexigen.com Phone858-875-8600FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$33.71 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares18,887,000Free FloatN/AMarket Cap$100,101.10 OptionableNot Optionable Beta4.98 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Thomas P. Lynch (Age 52)Consultant Key CompetitorsCalithera BiosciencesNASDAQ:CALAPraxsynOTCMKTS:PXYNGenerex BiotechnologyOTCMKTS:GNBTQ BioMedOTCMKTS:QBIOAdhera TherapeuticsOTCMKTS:ATRXView All Competitors OREXQ Stock Analysis - Frequently Asked Questions How have OREXQ shares performed in 2024? Orexigen Therapeutics' stock was trading at $0.0053 on January 1st, 2024. Since then, OREXQ stock has increased by 0.0% and is now trading at $0.0053. View the best growth stocks for 2024 here. How do I buy shares of Orexigen Therapeutics? Shares of OREXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:OREXQ) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orexigen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
